Kids & teens (for parents) · New York
Studies for children and teens in New York
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
97 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
argenx
- Location
- New York, NY + 10 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- New York, NY + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Queens, NY + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Amherst, NY + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Lake Success, NY + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Hoffmann-La Roche
- Location
- New York, NY
- Eligibility basics
- Ages 2–17
- RecruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Hoffmann-La Roche
- Location
- New York, NY + 9 other US sites
- Eligibility basics
- Ages 4 mo–2
- RecruitingPhase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline
- Location
- The Bronx, NY + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- New Hyde Park, NY + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Lake Success, NY + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Regeneron Pharmaceuticals
- Location
- New York, NY + 12 other US sites
- Eligibility basics
- Ages 6 mo–6
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Port Jefferson Station, NY + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- New York, NY + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Agios Pharmaceuticals, Inc.
- Location
- New York, NY + 3 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
Agios Pharmaceuticals, Inc.
- Location
- New York, NY + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC
- Location
- New York, NY + 8 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- New York, NY + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- New York, NY + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Orangeburg, NY + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Amherst, NY + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Amherst, NY + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
- Location
- Rochester, NY + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active…
AbbVie
- Location
- Valhalla, NY + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Amherst, NY + 87 other US sites
- Eligibility basics
- Ages 6–17